

Lars F Iversen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8050659/lars-f-iversen-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

174
papers

5,107
citations

42
h-index

64
g-index

184
ext. papers

6,123
ext. citations

3.8
avg, IF

5.6
L-index

#	Paper	IF	Citations
174	Quantification of Immunohistochemically Stained Cells in Skin Biopsies.. <i>Dermatopathology (Basel, Switzerland)</i> , 2022 , 9, 82-93	1.9	
173	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE-2 and -3.. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022 ,	4.6	3
172	Suppressed microRNA-195-5p expression in mycosis fungoides promotes tumor cell proliferation. <i>Experimental Dermatology</i> , 2021 , 30, 1141-1149	4	2
171	MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells. <i>Dermatology</i> , 2021 , 237, 277-282	4.4	5
170	Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. <i>Journal of Dermatological Treatment</i> , 2021 , 32, 916-921	2.8	1
169	HSP90 inhibitor RGRN-305 for oral treatment of plaque type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study. <i>British Journal of Dermatology</i> , 2021 ,	4	2
168	Staphylococcus aureus and Antibiotics in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2021 , 1-3	4.4	1
167	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2021 , 237, 283-290	4.4	6
166	The HSP90 inhibitor RGRN-305 exhibits strong immunomodulatory effects in human keratinocytes. <i>Experimental Dermatology</i> , 2021 , 30, 773-781	4	4
165	Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. <i>BMJ Open</i> , 2021 , 11, e041871	3	1
164	Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multi-centre cohort study. <i>Journal of Internal Medicine</i> , 2021 , 290, 693-703	10.8	4
163	Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2021 , 157, 676-683	5.1	5
162	Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. <i>Psoriasis: Targets and Therapy</i> , 2021 , 11, 83-97	2.4	3
161	Diagnostic Two-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 213-217.e5	4.3	2
160	Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment. <i>Autoimmunity Reviews</i> , 2021 , 20, 102731	13.6	5
159	Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 75-80	5.4	2
158	I-Kappa-B-Zeta Regulates Interleukin-17A/Tumor Necrosis Factor-Alpha Mediated Synergistic Induction of Interleukin-19 and Interleukin-20 in Humane Keratinocytes. <i>Annals of Dermatology</i> , 2021 , 33, 122-130	0.4	2

157	Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans-Results From the Nordic PAM Study. <i>Frontiers in Medicine</i> , 2021 , 8, 629741	4.9	1
156	Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35 Suppl 1, 5-9	4.6	6
155	Tissue-Resident Memory T Cells in Skin Diseases: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	2
154	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021 , 35, 2225-2238	4.6	2
153	Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. <i>Dermatologic Therapy</i> , 2021 , 34, e15106	2.2	2
152	Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. <i>Journal of Dermatological Treatment</i> , 2021 , 1-7	2.8	2
151	Staphylococcus aureus Induces Signal Transducer and Activator of Transcription 5-Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2021 , 141, 2449-2458	4.3	4
150	IkB α is a Key Regulator of Tumour Necrosis Factor- α and Interleukin-17A-mediated Induction of Interleukin-36g in Human Keratinocytes. <i>Acta Dermato-Venereologica</i> , 2021 , 101, adv00386	2.2	0
149	HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 775-780	2.2	1
148	alpha-toxin inhibits CD8 T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. <i>Oncolmmunology</i> , 2020 , 9, 1751561	7.2	10
147	MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. <i>Cancers</i> , 2020 , 12,	6.6	12
146	Radiographic scoring systems for psoriatic arthritis are insufficient for psoriatic arthritis mutilans: results from the Nordic PAM Study. <i>Acta Radiologica Open</i> , 2020 , 9, 2058460120920797	1.2	2
145	Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sjögren syndrome. <i>Blood Cancer Journal</i> , 2020 , 10, 57	7	11
144	Global reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020 , 183, 404-406	4	16
143	Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2020 , 7, 83	4.9	6
142	IL-37 Expression Is Downregulated in Lesional Psoriasis Skin. <i>ImmunoHorizons</i> , 2020 , 4, 754-761	2.7	5
141	Deep Learning for Diagnostic Binary Classification of Multiple-Lesion Skin Diseases. <i>Frontiers in Medicine</i> , 2020 , 7, 574329	4.9	3
140	Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020 , 34, e773-e776	4.6	3

139	Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA 5-15% and PGA B: Post-Hoc Analysis From Three Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020 , 10, 1111-1120	4	2
138	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020 , 182, 605-617	4	59
137	IL1 is a key player in the antipsoriatic effects of secukinumab. <i>Journal of Allergy and Clinical Immunology</i> , 2020 , 145, 379-390	11.5	10
136	Systematic review of machine learning for diagnosis and prognosis in dermatology. <i>Journal of Dermatological Treatment</i> , 2020 , 31, 496-510	2.8	18
135	Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKK Kinases and Regulates NF- κ B /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate. <i>Psoriasis: Targets and Therapy</i> , 2020 , 10, 1-11	2.4	3
134	Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4 T cells in cutaneous T-cell lymphoma. <i>OncImmunology</i> , 2019 , 8, e1641387	7.2	19
133	Localization of treatment-resistant areas in patients with psoriasis on biologics. <i>British Journal of Dermatology</i> , 2019 , 181, 332-337	4	14
132	Psoriasis and Risk of Mental Disorders in Denmark. <i>JAMA Dermatology</i> , 2019 , 155, 745-747	5.1	14
131	Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic PATient survey of Psoriasis and Psoriatic arthritis (NORPAPP). <i>Archives of Dermatological Research</i> , 2019 , 311, 351-360	3.3	13
130	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. <i>Blood</i> , 2019 , 134, 1072-1083	2.2	54
129	Safety of Mogamulizumab in Mycosis Fungoides and Sezary Syndrome: Final Results from the Phase 3 Mavoric Study. <i>Blood</i> , 2019 , 134, 5300-5300	2.2	2
128	Non-random Plaque-site Recurrence of Psoriasis in Patients Treated with Dead Sea Climatotherapy. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 909-910	2.2	4
127	Investigating the Role of I Kappa B Kinase in the Pathogenesis of Psoriasis. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 1035-1036	2.2	
126	High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome. <i>BMC Medical Genomics</i> , 2019 , 12, 174	3.7	28
125	Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2019 , 6, 259	4.9	3
124	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019 , 9, 5-18	4	44
123	Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PATient survey of Psoriasis and Psoriatic arthritis (NORPAPP). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019 , 33, 340-354	4.6	13
122	Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. <i>Acta Dermato-Venereologica</i> , 2019 , 99, 18-25	2.2	6

121	Letter by Hjuler et al Regarding Article, "Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study". <i>Circulation</i> , 2018 , 137, 1090-1091	16.7	
120	Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification - rationale and design of the randomized, multicenter STEPIn study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 1930-1939	4.6	20
119	Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018 , 78, 1077-1083.e4	4.5	3
118	Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, 2185-2190	4.6	7
117	Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. <i>Pharmacogenomics Journal</i> , 2018 , 18, 494-500	3.5	27
116	The effect of botulinum neurotoxin A in patients with plaque psoriasis - an exploratory trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32, e81-e82	4.6	6
115	SATB1 in Malignant T Cells. <i>Journal of Investigative Dermatology</i> , 2018 , 138, 1805-1815	4.3	28
114	Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. <i>Blood</i> , 2018 , 131, 759-770	2.2	34
113	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018 , 32 Suppl 3, 3-14	4.6	41
112	Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases. <i>Nature Communications</i> , 2018 , 9, 4344	17.4	20
111	Single-cell heterogeneity in Sjögren syndrome. <i>Blood Advances</i> , 2018 , 2, 2115-2126	7.8	45
110	The human IL-17A/F heterodimer regulates psoriasis-associated genes through IL-17A. <i>Experimental Dermatology</i> , 2018 , 27, 1048-1052	4	11
109	Langerhans cell markers CD1a and CD207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment. <i>Experimental Dermatology</i> , 2017 , 26, 804-810	4	8
108	Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis - nationwide results from the DERMBIO registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1183-1187	4.6	14
107	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1271-1284	4.6	16
106	Immune responses and parasitological observations induced during probiotic treatment with medicinal <i>Trichuris suis ova</i> in a healthy volunteer. <i>Immunology Letters</i> , 2017 , 188, 32-37	4.1	11
105	Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study. <i>Scandinavian Journal of Rheumatology</i> , 2017 , 46, 454-460	1.9	2
104	Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017 , 31, 1188-1195	4.6	12

103	Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017 , 176, 732-740	4	28
102	TRIM21 is important in the early phase of inflammation in the imiquimod-induced psoriasis-like skin inflammation mouse model. <i>Experimental Dermatology</i> , 2017 , 26, 713-720	4	12
101	STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes. <i>PLoS ONE</i> , 2017 , 12, e0176994	3.7	22
100	Protein phosphatase 2C γ Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin. <i>Journal of Inflammation Research</i> , 2017 , 10, 169-180	4.8	4
99	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>Journal of the American Academy of Dermatology</i> , 2017 , 77, 855-862	4.5	80
98	Malignant T cells activate endothelial cells via IL-17 F. <i>Blood Cancer Journal</i> , 2017 , 7, e586	7	8
97	Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins. <i>Blood Cancer Journal</i> , 2017 , 7, e517	7	16
96	Using FDG-PET/CT to Detect Vascular Inflammation in Patients with Psoriasis: Where to Look? And for What??. <i>Journal of Investigative Dermatology</i> , 2017 , 137, 2236-2237	4.3	2
95	Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. <i>Experimental Dermatology</i> , 2017 , 26, 338-345	4	17
94	IL-17F regulates psoriasis-associated genes through IL-17A. <i>Experimental Dermatology</i> , 2017 , 26, 234-241	4	19
93	Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover. <i>Seminars in Immunopathology</i> , 2017 , 39, 269-282	12	73
92	Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. <i>Acta Dermato-Venereologica</i> , 2017 , 97, 426-432	2.2	26
91	Old and New Biological Therapies for Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	125
90	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016 , 25, 1179-88	3.7	11
89	Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study. <i>BMJ Open</i> , 2016 , 6, e011870	3	18
88	Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict. <i>Dermatology and Therapy</i> , 2016 , 6, 273-85	4	18
87	Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules. <i>Molecular and Cellular Therapies</i> , 2016 , 4, 1		12
86	The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast. <i>British Journal of Dermatology</i> , 2016 , 174, 187-90	4	13

85	Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF- α <i>PLoS ONE</i> , 2016 , 11, e0167437	3.7	8
84	STAT5 induces miR-21 expression in cutaneous T cell lymphoma. <i>Oncotarget</i> , 2016 , 7, 45730-45744	3.3	31
83	Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis. <i>JAMA Dermatology</i> , 2016 , 152, 1114-1121	5.1	55
82	Comment on Tumour necrosis factor- α plays a significant role in the Aldara-induced skin inflammation in mice Reply from authors. <i>British Journal of Dermatology</i> , 2016 , 174, 1419-20	4	
81	Identification of key research needs for topical therapy treatment of psoriasis - a consensus paper by the International Psoriasis Council. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016 , 30, 1115-9	4.6	21
80	Tumour necrosis factor- α plays a significant role in the Aldara-induced skin inflammation in mice. <i>British Journal of Dermatology</i> , 2016 , 174, 1011-21	4	15
79	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016 , 16, 15	2.1	51
78	Characterization of TNF- α and IL-17A-Mediated Synergistic Induction of DEFB4 Gene Expression in Human Keratinocytes through IL-1 <i>Journal of Investigative Dermatology</i> , 2016 , 136, 1608-1616	4.3	32
77	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. <i>Blood</i> , 2016 , 127, 1287-96	2.2	60
76	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015 , 172, 1395-406	4	106
75	Low-dose (10-Gy) total skin electron beam therapy for cutaneous T-cell lymphoma: an open clinical study and pooled data analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015 , 92, 138-43	4	46
74	Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. <i>American Journal of Medicine</i> , 2015 , 128, 1325-34.e2	2.4	73
73	IL-1 is a key driver in the development of psoriasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015 , 112, E5825-33	11.5	76
72	Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. <i>British Journal of Dermatology</i> , 2015 , 172, 244-52	4	196
71	Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015 , 29, 1128-34	4.6	127
70	Aldara α -induced skin inflammation: studies of patients with psoriasis. <i>British Journal of Dermatology</i> , 2015 , 172, 345-53	4	38
69	Radiographic development during three decades in a patient with psoriatic arthritis mutilans. <i>Acta Radiologica Open</i> , 2015 , 4, 2058460115588098	1.2	2
68	Comparative Analysis of Two Gene-Targeting Approaches Challenges the Tumor-Suppressive Role of the Protein Kinase MK5/PRAK. <i>PLoS ONE</i> , 2015 , 10, e0136138	3.7	8

67	Changes in mRNA expression precede changes in microRNA expression in lesional psoriatic skin during treatment with adalimumab. <i>British Journal of Dermatology</i> , 2015 , 173, 436-47	4	26
66	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. <i>Oncotarget</i> , 2015 , 6, 20555-69	3.3	58
65	Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. <i>Blood</i> , 2014 , 124, 761-70	2.2	40
64	Inflammatory cytokines break down intrinsic immunological tolerance of human primary keratinocytes to cytosolic DNA. <i>Journal of Immunology</i> , 2014 , 192, 2395-404	5.3	35
63	Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. <i>International Journal of Dermatology</i> , 2014 , 53, e464-6	1.7	23
62	Interleukin 20 protein localizes to distinct mononuclear cells in psoriatic skin. <i>Experimental Dermatology</i> , 2014 , 23, 349-52	4	7
61	Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: a Danish nationwide, population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2014 , 71, 529-35	4.5	19
60	MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. <i>Anticancer Research</i> , 2014 , 34, 7207-17	2.3	45
59	Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models. <i>BMC Immunology</i> , 2013 , 14, 51	3.7	5
58	The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013 , 168, 339-45	4	12
57	STAT1 expression and activation is increased in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013 , 168, 302-10	4	65
56	Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3-Ser727 phosphorylation as a modulator of transcriptional activity. <i>Experimental Dermatology</i> , 2013 , 22, 323-8	4	74
55	MicroRNA normalization candidates for quantitative reverse-transcriptase polymerase chain reaction in real time in lesional and nonlesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013 , 169, 677-81	4	6
54	Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma. <i>Toxins</i> , 2013 , 5, 1402-21	4.9	49
53	IL-20, IL-21 and p40: potential biomarkers of treatment response for ustekinumab. <i>Acta Dermato-Venereologica</i> , 2013 , 93, 150-5	2.2	23
52	TNF α and IL-17A-mediated S100A8 expression is regulated by p38 MAPK. <i>Experimental Dermatology</i> , 2013 , 22, 476-81	4	25
51	CCL27 expression is regulated by both p38 MAPK and IKK β signalling pathways. <i>Cytokine</i> , 2011 , 56, 699-707	4	11
50	The role of mitogen- and stress-activated protein kinase 1 and 2 in chronic skin inflammation in mice. <i>Experimental Dermatology</i> , 2011 , 20, 140-5	4	18

49	Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. <i>Experimental Dermatology</i> , 2011 , 20, 789-94	4	44
48	Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. <i>Inflammation Research</i> , 2011 , 60, 643-53	7.2	26
47	Mice lacking MSK1 and MSK2 show reduced skin tumor development in a two-stage chemical carcinogenesis model. <i>Cancer Investigation</i> , 2011 , 29, 240-5	2.1	25
46	Tumor necrosis factor β -mediated induction of interleukin 17C in human keratinocytes is controlled by nuclear factor κ B. <i>Journal of Biological Chemistry</i> , 2011 , 286, 25487-94	5.4	42
45	Role of p38 mitogen-activated protein kinase isoforms in murine skin inflammation induced by 12-O-tetradecanoylphorbol 13-acetate. <i>Acta Dermato-Venereologica</i> , 2011 , 91, 271-8	2.2	10
44	Caspase-5 expression is upregulated in lesional psoriatic skin. <i>Journal of Investigative Dermatology</i> , 2011 , 131, 670-6	4.3	47
43	Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. <i>British Journal of Dermatology</i> , 2010 , 162, 1216-23	4	23
42	Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNF α therapy. <i>British Journal of Dermatology</i> , 2010 , 163, 1194-204	4	46
41	A Characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. <i>Dermatology Reports</i> , 2010 , 2, e14	0.9	6
40	The p38 MAPK regulates IL-24 expression by stabilization of the 3'UTR of IL-24 mRNA. <i>PLoS ONE</i> , 2010 , 5, e8671	3.7	29
39	MK2 regulates the early stages of skin tumor promotion. <i>Carcinogenesis</i> , 2009 , 30, 2100-8	4.6	31
38	Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2009 , 160, 319-24	4	229
37	The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2009 , 161, 1059-66	4	12
36	The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. <i>EMBO Journal</i> , 2009 , 28, 2449-60	13	14
35	Reduced oxazolone-induced skin inflammation in MAPKAP kinase 2 knockout mice. <i>Journal of Investigative Dermatology</i> , 2009 , 129, 891-8	4.3	27
34	The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. <i>Nature Immunology</i> , 2008 , 9, 1028-36	19.1	248
33	The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthritis. <i>Cytokine</i> , 2008 , 41, 16-23	4	81
32	Inflammasomes and inflammatory caspases in skin inflammation. <i>Expert Review of Molecular Diagnostics</i> , 2008 , 8, 697-705	3.8	29

31	IL-8 and p53 are inversely regulated through JNK, p38 and NF-kappaB p65 in HepG2 cells during an inflammatory response. <i>Inflammation Research</i> , 2008 , 57, 329-39	7.2	26
30	Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signal-integrating kinases. <i>Experimental Dermatology</i> , 2008 , 17, 498-504	4	34
29	IL-20 gene expression is induced by IL-1beta through mitogen-activated protein kinase and NF-kappaB-dependent mechanisms. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 1326-36	4.3	47
28	Mitogen- and stress-activated protein kinase 2 and cyclic AMP response element binding protein are activated in lesional psoriatic epidermis. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 2012-9	4.3	29
27	Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 2129-37	4.3	51
26	The activity of caspase-1 is increased in lesional psoriatic epidermis. <i>Journal of Investigative Dermatology</i> , 2007 , 127, 2857-64	4.3	61
25	Protein expression of TNF-alpha in psoriatic skin is regulated at a posttranscriptional level by MAPK-activated protein kinase 2. <i>Journal of Immunology</i> , 2006 , 176, 1431-8	5.3	116
24	Mitogen- and stress-activated protein kinase 1 is activated in lesional psoriatic epidermis and regulates the expression of pro-inflammatory cytokines. <i>Journal of Investigative Dermatology</i> , 2006 , 126, 1784-91	4.3	49
23	Tumor necrosis factor-alpha-induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor kappaB. <i>Cytokine</i> , 2005 , 29, 49-55	4	54
22	The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2005 , 152, 37-42	4	154
21	The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. <i>British Journal of Dermatology</i> , 2005 , 153, 911-8	4	94
20	Inverse regulation of the nuclear factor-kappaB binding to the p53 and interleukin-8 kappaB response elements in lesional psoriatic skin. <i>Journal of Investigative Dermatology</i> , 2005 , 124, 1284-92	4.3	48
19	Signal transduction pathways in human epidermis. <i>European Journal of Dermatology</i> , 2005 , 15, 4-12	0.8	11
18	Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. <i>British Journal of Dermatology</i> , 2004 , 151, 600-7	4	31
17	1alpha,25(OH)(2)D(3) regulates NF-kappaB DNA binding activity in cultured normal human keratinocytes through an increase in IkappaBalpha expression. <i>Archives of Dermatological Research</i> , 2004 , 296, 195-202	3.3	57
16	Growth medium-dependent ERK1/2 and AP-1 activity in cultured normal human keratinocytes modulates 1alpha,25-dihydroxyvitamin D3-induced differentiation. <i>Archives of Dermatological Research</i> , 2003 , 295, 199-202	3.3	
15	1alpha,25-dihydroxyvitamin D3 stimulates activator protein 1 DNA-binding activity by a phosphatidylinositol 3-kinase/Ras/MEK/extracellular signal regulated kinase 1/2 and c-Jun N-terminal kinase 1-dependent increase in c-Fos, Fra1, and c-Jun expression in human keratinocytes. <i>Journal of Investigative Dermatology</i> , 2003 , 120, 561-70	4.3	44
14	Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. <i>Journal of Investigative Dermatology</i> , 2003 , 121, 1104-17	4.3	91

13	Modulation of keratinocyte gene expression and differentiation by PPAR-selective ligands and tetradecylthioacetic acid. <i>Journal of Investigative Dermatology</i> , 2001 , 116, 702-12	4.3	187
12	1alpha,25-dihydroxyvitamin D3 induced differentiation of cultured human keratinocytes is accompanied by a PKC-independent regulation of AP-1 DNA binding activity. <i>Journal of Investigative Dermatology</i> , 2000 , 114, 1174-9	4.3	28
11	Upregulation of nuclear PKC and MAP-kinase during hyperproliferation of guinea pig epidermis: modulation by 13-(S)-hydroxyoctadecadienoic acid (13-HODE). <i>Cellular Signalling</i> , 1998 , 10, 143-9	4.9	17
10	The role of leukotriene A4 hydrolase/aminopeptidase in transcellular leukotriene B4 synthesis in human epidermis. <i>Acta Dermato-venereologica Supplementum</i> , 1997 , 199, 1-28		1
9	LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. Evidence for different LTA4 hydrolase activity in human lymphocytes and human skin. <i>Archives of Dermatological Research</i> , 1996 , 288, 217-24	3.3	9
8	Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. <i>Acta Dermato-Venereologica</i> , 1996 , 76, 424-8	2.2	1
7	Incorporation of 15-hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques. <i>Experimental Dermatology</i> , 1995 , 4, 74-8	4	9
6	Purification and characterization of leukotriene A4 hydrolase from human epidermis. <i>FEBS Letters</i> , 1995 , 358, 316-22	3.8	15
5	Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. <i>Archives of Dermatological Research</i> , 1994 , 286, 261-6	3.3	28
4	Distribution of monohydroxy fatty acids in specific human epidermal phospholipids. <i>Experimental Dermatology</i> , 1993 , 2, 38-44	4	7
3	Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway. <i>Archives of Dermatological Research</i> , 1992 , 284, 222-6	3.3	36
2	Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophils in vitro. Evidence of formation of antiinflammatory compounds. <i>Agents and Actions</i> , 1991 , 33, 286-91		48
1	High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome		2